- Home
- CRNX vs VGI Comparison
CRNX vs VGI Comparison
Compare CRNX & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$42.59
Company Overview
Basic Information| Metric | CRNX | VGI |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 89.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRNX | VGI |
|---|---|---|
| Price | $42.59 | $7.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $75.78 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 46.0K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,535,000.00 | N/A |
| Revenue This Year | $499.13 | N/A |
| Revenue Next Year | $893.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.74 | N/A |
| 52 Week Low | $24.10 | $6.68 |
| 52 Week High | $57.99 | $7.99 |
Technical Indicators
Market Signals| Indicator | CRNX | VGI |
|---|---|---|
| Relative Strength Index (RSI) | 36.05 | 48.69 |
| Support Level | $43.94 | $7.83 |
| Resistance Level | $48.58 | $8.04 |
| Average True Range (ATR) | 2.53 | 0.07 |
| MACD | -0.77 | 0.00 |
| Stochastic Oscillator | 5.33 | 20.93 |
Price Performance
Historical Comparison CRNX
VGI
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.